Website: [ProteinQure.com](https://www.proteinqure.com/) ### Introduction ProteinQure is a biotech company founded in 2017, headquartered in Toronto, Ontario, Canada. The company was co-founded by Lucas Siow, Tomas Babej, and Christopher Ing, with a mission to revolutionize drug discovery by designing novel exotic peptides for broad therapeutic applications using computational methods, including quantum computing, artificial intelligence (AI), and molecular simulations. While exact employee counts are not publicly available as of the latest data, ProteinQure maintains a presence on professional networks like LinkedIn, indicating a growing team focused on computational biology and drug design [ProteinQure LinkedIn](https://ca.linkedin.com/company/proteinqure). ProteinQure operates as a private company, with no public ticker symbol or stock exchange listing. Its innovative approach positions it at the intersection of biotechnology and quantum computing, aiming to address complex challenges in protein-based drug development by leveraging physics-based methods to explore novel protein structures and interactions, reducing dependency on large datasets. ### Key Products and Technology ProteinQure does not produce traditional energy or compute infrastructure hardware but focuses on computational platforms for drug discovery with quantum computing as a core component. Below are the key aspects of their technology offerings: - **Computational Protein Drug Discovery Platform (Software Platform)** - **Type**: Software for structure-based drug design. - **Technical Specifications**: Utilizes a combination of molecular simulations, machine learning, and quantum computing to design protein-based therapeutics. Specific computational power or efficiency metrics are not publicly detailed. - **Fuel Type or Energy Source**: Not applicable as this is a software-based solution; however, the platform likely requires significant computational resources, potentially relying on cloud-based or quantum hardware infrastructure. - **Key Differentiators**: Physics-based approach reduces reliance on large datasets, enabling exploration of novel protein structures and interactions. Integration of quantum computing offers potential for solving complex molecular problems faster than classical methods. - **Development Stage**: Operational as a revenue-generating platform, with ongoing refinements and applications in therapeutic design. - **Target Customers**: Pharmaceutical companies, biotech firms, and research institutions seeking innovative drug discovery solutions. While ProteinQure’s focus is on biotechnology, its use of quantum computing aligns with broader trends in high-performance computing infrastructure, which often intersects with energy demands for data centers and specialized hardware. ### Regulatory and Licensing Status As a biotech company focused on computational drug discovery, ProteinQure does not fall under traditional energy or nuclear regulatory frameworks like the Nuclear Regulatory Commission (NRC). Instead, its regulatory oversight pertains to health and pharmaceutical standards, likely involving agencies such as Health Canada or the U.S. Food and Drug Administration (FDA) for therapeutic applications. Specific details on regulatory submissions or approvals for their drug candidates are not publicly available in the latest data. There are no publicly documented milestones or timelines related to commercial deployment of specific therapeutics as of the most recent information. The company’s primary focus appears to be on platform development and partnerships rather than direct regulatory approvals at this stage. ### Team and Leadership ProteinQure’s leadership team includes key figures driving its computational and biotech innovations. Below are notable members based on available data: - **Lucas Siow - CEO & Co-Founder**: Leads the strategic direction of ProteinQure, focusing on integrating quantum computing into drug discovery. Specific background details are limited in public sources. - **Tomas Babej - CTO & Co-Founder**: Oversees the technological development of the computational platform, with expertise in quantum computing and molecular simulations. - **Christopher Ing - Co-Founder**: Contributes to the scientific and operational aspects of protein design strategies. Verified X handles for the leadership team are not publicly available or confirmed in the current data, so they are omitted here. Further details on additional team members or recent changes in leadership are not widely documented in accessible sources. ### Funding and Financial Position ProteinQure has raised significant early-stage funding to support its innovative approach to drug discovery. Key financial details include: - **Total Funding**: The company raised a $4 million seed round in July 2019, as reported on their official website [ProteinQure News](https://www.proteinqure.com/proteinqure-raises-4m-seed-round-to-unlock-the-potential-of-protein-therapeutics/). No further funding rounds are documented in the latest available data up to 2025. - **Latest Round**: Seed round, July 2019, $4 million, with lead investors not specified in public sources. - **Key Investors**: Specific institutional investors or strategic backers are not detailed in the most recent public information, though interest from biotech and tech-focused venture capital firms is likely given the company’s focus. - **Revenue Status**: ProteinQure is described as a revenue-generating platform on LinkedIn [ProteinQure LinkedIn](https://ca.linkedin.com/company/proteinqure), though exact figures or contract details are not disclosed. As a private company, financial transparency is limited, and no recent updates on funding or financial health beyond 2019 are widely available as of the current data. ### Recent News and Developments | Date | Event | Details | |---------------|------------------------------------|-------------------------------------------------------------------------| | Dec 2025 | No Specific Events Reported | Limited updates on ProteinQure’s activities in quantum computing or biotech for late 2025. | | Sep 23, 2025 | Quantum Computing Industry Update | ProteinQure remains listed among quantum computing innovators, though no specific company news is highlighted [The Quantum Insider](https://thequantuminsider.com/2025/09/23/top-quantum-computing-companies/). | | Jun 19, 2025 | Company Profile Update | CB Insights updates ProteinQure’s profile, focusing on peptide design for therapeutics [CB Insights](https://www.cbinsights.com/company/proteinqure). | | Jan 2025 | No Specific Events Reported | No major announcements or milestones documented for early 2025. | | General 2025 | Continued Platform Development | ProteinQure continues to operate as a revenue-generating platform for drug discovery, per LinkedIn updates [ProteinQure LinkedIn](https://ca.linkedin.com/company/proteinqure). | Note: Information on recent events for ProteinQure is limited in 2025 public data. The table reflects the scarcity of specific updates, focusing on broader industry mentions and static company profiles. ### Partnerships and Collaborations Specific partnerships for ProteinQure are not extensively documented in the latest available information. The company likely collaborates with pharmaceutical firms and research institutions given its target customer base, but no named partners or strategic agreements are confirmed in public sources as of 2025. Their LinkedIn profile suggests a focus on building industry connections for computational drug discovery [ProteinQure LinkedIn](https://ca.linkedin.com/company/proteinqure). Additionally, their integration of quantum computing may imply potential ties with quantum hardware providers or cloud computing platforms, though specifics remain undisclosed. ### New Hampshire Relevance ProteinQure’s primary focus on computational drug discovery and quantum computing does not directly align with [[New Hampshire]]’s energy infrastructure needs, such as grid power or industrial heat applications near [[Seabrook Station]] or the ISO-NE grid. However, there is potential indirect relevance: - **Proximity to Infrastructure**: While ProteinQure is based in Toronto, Canada, its computational platform could support biotech or pharmaceutical research in the Northeast US, including New Hampshire, if local data centers or research hubs adopt their technology. - **Technology Readiness**: The platform is operational and revenue-generating, making it deployable for research purposes in NH if there is demand from local institutions or companies. - **Legislative Alignment**: ProteinQure’s work does not align with NH legislative initiatives like HB 710 or SMR provisions, as it is unrelated to nuclear or energy policy. - **Potential Applications**: The high computational demands of quantum computing could intersect with NH data center energy needs, though this is speculative and not a primary focus of the company. - **Existing Connections**: There are no documented connections or expressed interest in New Hampshire or the Northeast US specifically based on current data. Overall, ProteinQure’s relevance to New Hampshire is minimal and indirect, tied only to potential future growth in regional biotech research or quantum computing infrastructure. ### Competitive Position ProteinQure operates in a niche at the intersection of quantum computing and biotech, with competitors including: - **Schrödinger, Inc.**: A well-established player in computational drug discovery, Schrödinger uses advanced molecular modeling but does not heavily emphasize quantum computing, giving ProteinQure a potential edge in complex problem-solving. However, Schrödinger’s larger scale and client base pose a competitive challenge. - **Quantum-Si**: Focused on protein sequencing with quantum technologies, Quantum-Si targets a different aspect of biotech (diagnostics rather than drug design), but overlaps in the use of quantum methods. ProteinQure’s broader therapeutic focus may offer differentiation. - **D-Wave Systems**: While primarily a quantum computing hardware provider, D-Wave collaborates on drug discovery applications, potentially competing with ProteinQure’s platform in specific use cases. ProteinQure’s software-centric, physics-based approach is a unique advantage. Risks for ProteinQure include the high cost and complexity of quantum computing integration, limited public data on recent progress, and competition from larger, more established firms in both biotech and quantum spaces. ### Closing Note ProteinQure is an early-stage, revenue-generating biotech company with a promising trajectory in computational drug discovery, leveraging quantum computing for innovative therapeutic design, though its impact and growth updates remain limited in recent public data. **RSS_FEED**: none Note: Despite a thorough search, no official RSS feed for ProteinQure’s press releases or news was found on their website or other public sources. Information in this report is based on the most current data available as of December 2025, though updates for 2025 are sparse, and some details rely on older announcements. Word count: approximately 1200. *Report generated December 24, 2025*